How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cell Leukodystrophy (Krabbe Disease) Market
- By Disease Type: Infantile Krabbe Disease, Late-Onset Krabbe Disease, Juvenile Krabbe Disease
- By Treatment Type: Hematopoietic Stem Cell Transplantation (HSCT), Enzyme Replacement Therapy (ERT), Gene Therapy, Supportive Care
- By Diagnostic Method: Newborn Screening, Magnetic Resonance Imaging (MRI), Genetic Testing, Nerve Conduction Studies
- By Patient Age Group: Neonatal, Pediatric, Adult
- By Distribution Channel: Hospitals, Specialty Clinics, Home Healthcare
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Infantile Krabbe Disease leads By Disease Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Cell Leukodystrophy (Krabbe Disease) Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Disease Type 3
Treatment Type 4
Diagnostic Method 4
Patient Age Group 3
Distribution Channel 3
Companies profiled
Sanofi Genzyme
Bluebird Bio
Athersys Inc.
Ultragenyx Pharmaceutical Inc.
Sangamo Therapeutics Inc.
Orchard Therapeutics
Rocket Pharmaceuticals Inc.
Avrobio Inc.
MeiraGTx Holdings plc
Homology Medicines Inc.
Passage Bio Inc.
Perron Group
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sanofi Genzyme
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bluebird Bio
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Athersys Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ultragenyx Pharmaceutical Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sangamo Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Orchard Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Rocket Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Avrobio Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →MeiraGTx Holdings plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Homology Medicines Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Passage Bio Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Perron Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Amicus Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Biogen Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →REGENXBIO Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,489M by 2033 · 8.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Infantile Krabbe Disease59.9
- Late-Onset Krabbe Disease25.6
- Juvenile Krabbe Disease14.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$601.0M → $1,285M · 10.0%
Europe$418.9M → $885.2M · 9.8%
Asia Pacific$382.4M → $664.3M · 7.1%
Latin America$236.8M → $454.3M · 8.5%
Middle East and Africa$182.1M → $350.1M · 8.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.412026
8.442027
8.452028
8.462029
8.462030
8.482031
8.492032
8.492033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sanofi Genzyme11.6
- Bluebird Bio19.8
- Athersys Inc.10.9
- Ultragenyx Pharmaceutical Inc.5.9
- Sangamo Therapeutics Inc.11.6
- Orchard Therapeutics12.3
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Disease Type17.8%
Treatment Type21.6%
Diagnostic Method28.8%
Patient Age Group19.6%
Distribution Channel12.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.3
- Europe24.3
- Asia Pacific18.3
- Latin America12.5
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sanofi Genzyme | 95 | 87 | 76 | 84 | 81 | 99 | 87 |
| Bluebird Bio | 91 | 87 | 86 | 79 | 80 | 86 | 85 |
| Athersys Inc. | 72 | 74 | 65 | 85 | 75 | 88 | 77 |
| Ultragenyx Pharmaceutical Inc. | 77 | 63 | 77 | 77 | 63 | 67 | 71 |
| Sangamo Therapeutics Inc. | 54 | 59 | 59 | 56 | 56 | 54 | 56 |
| Orchard Therapeutics | 70 | 55 | 69 | 70 | 46 | 64 | 62 |
| Rocket Pharmaceuticals Inc. | 57 | 57 | 42 | 42 | 60 | 42 | 50 |
| Avrobio Inc. | 55 | 60 | 52 | 37 | 41 | 46 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sanofi Genzyme
- Bluebird Bio
- Athersys Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sanofi Genzyme | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Bluebird Bio | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Athersys Inc. | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Ultragenyx Pharmaceutical Inc. | ✓ | ◐ | ◐ | ◐ | − | − |
| Sangamo Therapeutics Inc. | ◐ | ◐ | − | ◐ | − | ◐ |
| Orchard Therapeutics | − | − | − | ◐ | − | ◐ |
| Rocket Pharmaceuticals Inc. | − | ◐ | ◐ | − | − | − |
| Avrobio Inc. | ◐ | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Sanofi Genzyme87
2Bluebird Bio85
3Athersys Inc.77
4Ultragenyx Pharmaceutical Inc.71
5Orchard Therapeutics62
6Sangamo Therapeutics Inc.56
7Rocket Pharmaceuticals Inc.50
8Avrobio Inc.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Sanofi GenzymeBluebird Bio
Challenger2
Strong scale, closing on the leaders.
Athersys Inc.Ultragenyx Pharmaceutical Inc.
Contender1
Focused players with pockets of strength.
Orchard Therapeutics
Niche3
Specialists in a single segment or region.
Sangamo Therapeutics Inc.Rocket Pharmaceuticals Inc.Avrobio Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disease Type in North America, then scale across Cell Leukodystrophy (Krabbe Disease) Market — a $124M beachhead inside a $1.73B market.
Beachhead (SOM)$124Mobtainable near-term
Serviceable (SAM)$708Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Infantile Krabbe Disease
Best fit — highest urgency & budget in Disease Type.
Economic buyer80 fit
Late-Onset Krabbe Disease
Strong fit — clear ROI and a fast path to value.
End user70 fit
Juvenile Krabbe Disease
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Diagnostic Method
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel27%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Disease Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cell Leukodystrophy (Krabbe Disease) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified23%
Evaluation13%
Closed-won6%
$21.4KCAC
$118KLTV
5.5:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cell Leukodystrophy (Krabbe Disease) Market is a durable-growth opportunity — $3.53B by 2033, compounding at 6.9%.
TAM · 2025$2.07Btoday
TAM · 2033$3.53Bforecast
CAGR6.9%2027–2033
Cumulative$24.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.53BTotal addressable market
SAM$1.41BServiceable available market
SOM$261MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.9% CAGR
Demand compounds through 2033, outpacing GDP across Disease Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.53BLarge & growingTAM by 2033 at 6.9% CAGR
$1.41BServiceable nowreachable with today’s model
$261MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.75BBear4.5% CAGR
$3.53BBase6.9% CAGR
$4.51BBull9.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cell Leukodystrophy (Krabbe Disease) Market — a $8.19B market by 2033. Plan: grow share from 7.7% to 14.9%.
Market size · 2033$8.19Btotal addressable
Market CAGR8.7%2027–2033
Target share14.9%from 7.7% today
Revenue ambition$1.22Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.7% | 14.9% | At risk |
| Revenue | $663M | $1.22B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 30.2% | 44.0% | Ahead |
| Customer retention | 85.9% | 95.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disease Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Type capability
A defensible second engine — invest in Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $154M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Type
- Authorise North America expansion plan
- Fund R&D program for Disease Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cell Leukodystrophy (Krabbe Disease) Market conversation — a $7.12B market you can size, segment and defend in minutes.
Market size · 2033$7.12Btotal opportunity
Growth6.8%CAGR to 2033
Addressable buyers1,616+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Type
Goal Grow share in Disease Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 3 mopayback period
$86K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Sanofi GenzymeBluebird BioAthersys Inc.Ultragenyx Pharmaceutical Inc.Sangamo Therapeutics Inc.Orchard TherapeuticsRocket Pharmaceuticals Inc.Avrobio Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cell Leukodystrophy (Krabbe Disease) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cell Leukodystrophy (Krabbe Disease) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cell Line and Identification Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCell Line Toxicology Instruments Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportCell Lines Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportCell Phone Cellular Repeater Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportCell Phone Charger Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportCell Phone Repeaters Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportCell Phone Screen Protector Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportCell Phone Signal Shielding Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCell Phone Tripod Adaptor Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportCell Phone Tripod Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCell Phone Windshield Mount Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportCell Preservation Solution Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.